XERS
Xeris Biopharma Holdings, Inc.
$10.20
-6.08%
2026-10-23
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Key Fundamentals
P/E Ratio
119.14
Forward P/E
23.33
EPS (TTM)
$-0.10
Revenue Growth (YoY)
28.7%
Profit Margin
-5.1%
Debt/Equity
1987.19
Price/Book
-162.50
Beta
0.85
Market Cap
$1.66B
Avg Volume (10D)
2.3M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$11.41
60D Low
$7.05
Avg Volume
2.4M
Latest Close
$10.20
Get breakout alerts for XERS
Sign up for Breakout Scanner to receive daily notifications when XERS triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Xeris Biopharma Holdings, Inc. (XERS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors XERS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. XERS operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.